Please enable Javascript
Andrea Necchi, MD
Andrea Necchi, MD, Medical Oncologist, San Raffaele Hospital and Scientific Institute
Articles by Andrea Necchi, MD
SURE-02: Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab, Response-Adapted Bladder Sparing, and Adjuvant Pembrolizumab for Patients With MIBC
Andrea Necchi, MD
Muscle Invasive Urothelial Carcinoma
|
June 9, 2025
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
View More
Drs. Necchi, Tawagi Discuss SunRISe-4 for MIBC
Andrea Necchi, MD
Muscle Invasive Urothelial Carcinoma
|
September 16, 2024
Drs. Necchi, Tawagi discuss the interim analysis of SunRISe-4 - TAR-200 plus cetrelimab or cetrelimab alone in MIBC patients.
View More
Challenges in Treating Penile Cancer
Andrea Necchi, MD
Testicular, Penile, and Rare Malignancies
|
September 16, 2024
Drs. Necchi and Tawagi highlight some the challenges in penile cancer, including "suboptimal" neoadjuvant, adjuvant options.
View More
KEYNOTE-057: Pembrolizumab Monotherapy for High-risk NMIBC Unresponsive to BCG
Andrea Necchi, MD
ASCO GU Symposium 2023
|
February 24, 2023
Andrea Necchi, MD, speculates on the applicability of pembrolizumab monotherapy for BCG-unresponsive NMIBC.
View More